Pregabalin 75mg with Etoricoxib 60mg Tablets are formulated as a dual-active pharmaceutical combination containing Pregabalin and Etoricoxib in defined strengths. The combination brings together two pharmacologically distinct active ingredients within a single solid oral dosage form, requiring careful consideration of API compatibility, excipient selection, powder characteristics, and manufacturing controls. For pharmaceutical companies developing or expanding their portfolio, this formulation can be incorporated into a structured PCD Pharma Franchise product range with appropriate quality documentation and packaging specifications.
The formulation contains Pregabalin 75mg and Etoricoxib 60mg as the principal active pharmaceutical ingredients. Since both APIs possess different physicochemical properties, the formulation development process requires attention to particle size, flowability, bulk density, moisture sensitivity, and blend characteristics.
Excipients are selected according to their functional contribution to the finished tablet. Depending on the formulation design, suitable diluents may be incorporated to achieve the required tablet weight and improve processing characteristics. Binders can support granule formation and mechanical strength, while disintegrants may assist in achieving an appropriate tablet disintegration profile. Lubricants and glidants can help optimize powder movement and compression performance.
The formulation development stage also considers API distribution throughout the powder blend. This becomes particularly important for Pregabalin because accurate dose uniformity must be maintained alongside the higher-strength Etoricoxib component. The overall formulation is therefore designed around controlled blending and reproducible manufacturing parameters.
Uniform distribution of Pregabalin and Etoricoxib is an important manufacturing consideration. Before blending, the APIs and selected excipients may undergo appropriate sieving or milling to achieve a suitable particle-size distribution. Consistent particle characteristics can improve blend homogeneity and reduce segregation during subsequent processing.
The manufacturing route may involve direct compression or granulation depending on the physical characteristics of the formulation. In a granulation-based process, controlled addition of a binder solution can help form granules with suitable density and flow properties. Drying conditions are monitored carefully to achieve the desired moisture level without compromising material quality.
Blending time, mixer loading, order of ingredient addition, and material transfer methods can influence uniformity. Sampling at defined stages can help verify that the active ingredients remain consistently distributed throughout the batch. Process validation and in-process controls further support reproducibility between manufacturing lots.
Following preparation of the final blend or granules, the material is transferred to the tablet compression stage. Compression parameters are established according to the formulation's flow and compaction characteristics. Machine speed, compression force, feeder performance, and tooling configuration can influence tablet weight, hardness, thickness, and appearance.
The finished Pregabalin 75mg with Etoricoxib 60mg Tablets may be developed in a suitable shape and size that supports consistent production and packaging. Depending on the product design, film coating may be applied to improve surface characteristics, product identification, and handling properties.
In-process testing can include tablet weight variation, thickness, hardness, friability, disintegration, and visual inspection. These checks help identify manufacturing deviations during production rather than relying only on final-product testing. Proper control of compression parameters also helps maintain consistency in tablet dimensions and mechanical integrity.
Quality control for Pregabalin 75mg with Etoricoxib 60mg Tablets involves analytical evaluation of both active ingredients along with relevant finished-product parameters. Identification and assay testing can be performed using validated analytical procedures appropriate for the formulation.
Content uniformity or related dosage-unit testing is important for confirming consistent distribution of the active ingredients from tablet to tablet. Dissolution testing provides information about the release characteristics of the formulation under defined laboratory conditions. The test method and acceptance criteria should be established according to the applicable pharmacopoeia or validated product specifications.
Additional quality assessments may include related substances, degradation products, moisture content where relevant, microbial quality where applicable, and physical characteristics. Analytical instruments and testing procedures should be appropriately qualified and validated. Batch documentation, laboratory records, and manufacturing records provide traceability throughout the production cycle.
Stability evaluation is an important component of pharmaceutical product development. Pregabalin 75mg with Etoricoxib 60mg Tablets can be evaluated under defined temperature and humidity conditions to assess changes in assay, dissolution, degradation profile, physical appearance, and other relevant quality attributes over time.
Packaging selection is based on the formulation's stability profile and protection requirements. Depending on the established packaging study, tablets may be packed in suitable blister packs or other pharmaceutical-grade containers. Packaging materials should provide an appropriate barrier against environmental factors such as moisture, light, and oxygen where relevant.
The container-closure system should also maintain product integrity during transportation, storage, and handling. Packaging artwork can clearly present the product name, composition, strength, batch details, manufacturing information, storage instructions, and other legally required particulars. Stability data can subsequently support the assigned shelf life and recommended storage conditions.
Pregabalin 75mg with Etoricoxib 60mg Tablets can form part of a diversified pharmaceutical portfolio designed around clearly defined dosage forms, strengths, packaging formats, and quality specifications. For companies operating in the PCD Pharma Franchise segment, organized product development helps maintain consistency across manufacturing batches and supports efficient portfolio management.
A well-structured product specification should cover the complete manufacturing lifecycle, beginning with approved raw materials and continuing through dispensing, blending, compression, coating where applicable, packaging, finished-product testing, and batch release. Supplier qualification and incoming material testing can further support control over critical pharmaceutical inputs.
From a portfolio perspective, maintaining standardized documentation for composition, manufacturing procedures, analytical specifications, packaging materials, and stability data can simplify product management across different markets. Proper batch traceability and quality documentation also provide a systematic framework for maintaining consistency as production volumes increase.
Overall, Pregabalin 75mg with Etoricoxib 60mg Tablets represents a technically structured dual-API tablet formulation in which formulation design, blend uniformity, compression control, analytical testing, packaging, and stability assessment work together to establish a consistent finished pharmaceutical product.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech